Indiana execution halted: lethal drugs sourced from pharmacy under state probe
Lawyers for death row inmate Jeffrey Weisheit urged Indiana's governor to stop his execution after drugs used were allegedly sourced from a pharmacy on probation.
Indiana execution drugs linked to pharmacy facing licence suspension
Hours before Indiana was set to carry out the lethal injection of Jeffrey Weisheit, 50, lawyers and supporters mounted a last-minute push to halt the pre-dawn execution after new details emerged about how the state obtained its lethal drugs — details reported by nbcnews.com.
Weisheit was convicted of the 2010 murders of two young children, killed in a house fire. He did not contest his guilt but sought clemency from Governor Mike Braun, asking that his sentence be commuted to life in prison without parole.
His attorneys called on Braun to order an independent review of the state's drug procurement procedures, alleging that Indiana sourced its execution chemicals from an Indianapolis-based pharmacy currently on probation and facing possible suspension of its licence.
"Laid bare, the apparent conduct here is patently unworthy of the public's confidence in the solemn exercise of state power in taking a human being's life in the name of the people," said Joe Perkovich, an attorney for Weisheit, in a statement issued Wednesday.
$275,000 for six vials — far above market rate
An updated inventory log provided to NBC News shows the Indiana Department of Correction added six vials of pentobarbital — the drug used in the execution — to its prison supply on 29 October. An invoice included in the reprieve application records a payment of $275,000 for those vials, well above the typical market price of $15,120 to $16,250 for commercially produced injectable pentobarbital. The invoice is heavily redacted and lists neither the date nor the supplier.
Indiana law shields the identities of pharmacies, suppliers, and other participants involved in executions. However, a September 2025 invoice for the same dollar amount — corresponding to the last time the state replenished its pentobarbital supply — inadvertently exposed what the defence says is the likely supplier. An address visible beneath an improperly applied redaction matches the registered address for Pharmaneek, an Indianapolis pharmacy.
Pharmacy facing board hearing days after scheduled execution
Pharmaneek was scheduled to appear before the Indiana Board of Pharmacy on Monday — four days after Weisheit's scheduled execution — over allegations that the pharmacy breached the terms of its probation following failed inspections by the Indiana Professional Licensing Agency and the Food and Drug Administration.
Those inspections uncovered a range of problems. Investigators found drugs stored in unlabelled bottles, bottles of expired medication on active pharmacy shelves during routine checks, and inconsistent temperature logs for storage areas. In a settlement agreement with the state, Pharmaneek attributed some of the deficiencies to ongoing remodelling of its premises.
An FDA inspection report from March 2026 stated that the "facility is not maintained in a good state of repair, creating unsanitary conditions whereby drug products may be contaminated with filth." The FDA added that its findings do not represent a final agency determination on regulatory compliance.
A legal filing dated 24 September shows the Indiana Board of Pharmacy had already ordered Pharmaneek to appear on 5 October to explain why its licence "should not be suspended on an emergency basis or subjected to the imposition of further sanctions." A lawyer for Pharmaneek subsequently requested that the hearing be moved to Monday.
Pharmacy allegedly acting as middleman
While Pharmaneek is currently barred from compounding — the mixing of custom drug formulations — Weisheit's reprieve application alleges the pharmacy has been functioning as a commercial middleman for the Department of Correction. The filing claims Pharmaneek supplied the state with manufactured pentobarbital that the department is not permitted to purchase directly from traditional pharmaceutical manufacturers.
In court filings ahead of the execution of Roy Lee Ward in October 2025, the state maintained that the pentobarbital it used was produced by a pharmaceutical company rather than a compounding pharmacy, and distributed without post-manufacturing modifications.
Major drug companies have explicitly prohibited states from using their products in executions and have taken legal action to recover chemicals supplied in breach of those restrictions. Sagent Pharmaceuticals, one of two US manufacturers of pentobarbital, did not respond to questions from NBC News about whether it has a commercial relationship with Pharmaneek. Its stated policy bars distributors and wholesalers from selling its products to prisons for use in lethal injection.
The other manufacturer, Hikma, confirmed it has no purchase agreement with Pharmaneek. "We have strict prohibitions and controls intended to prevent the use of our medicines in capital punishment," said Steven Weiss, a Hikma spokesperson.
Governor's office and Department of Correction decline to comment
Weisheit's attorneys also referenced Tennessee's failed execution of Christa Pike on 30 September, in which the lethal injection left Pike in a coma, arguing that Indiana's protocol is "more susceptible to catastrophic failures" of a similar kind and that Pharmaneek has a history of "rampant mishandling of drugs."
Pharmaneek did not respond to multiple phone requests for comment from NBC News. The Indiana Department of Correction similarly declined to respond to requests for comment or an interview. The governor's office also declined to comment Wednesday on the allegation that the department obtained execution drugs from a pharmacy operating under probation.
A spokesperson for Indiana Attorney General Todd Rokita told NBC News the office is confident in the state's procedures, though the response was cut short in the available source material.
Source: Google News MT